Search

Your search keyword '"Loglisci, Maria Giovanna"' showing total 11 results
Start Over Author "Loglisci, Maria Giovanna"
11 results on '"Loglisci, Maria Giovanna"'

4. Incidence of Clinically Significant (≤10 g/dL) Late Anemia in Elderly Patients with Newly Diagnosed Chronic Myeloid Leukemia Treated with Imatinib

Author

Cesini, Laura, primary, Carmosino, Ida, additional, Breccia, Massimo, additional, De Benedittis, Daniela, additional, Mohamed, Sara, additional, De Luca, Maria Lucia, additional, Colafigli, Gioia, additional, Molica, Matteo, additional, Scalzulli, Emilia, additional, Massaro, Fulvio, additional, Mariggiò, Elena, additional, Rizzo, Lorenzo, additional, Loglisci, Maria Giovanna, additional, Scamuffa, Maria Cristina, additional, Vozella, Federico, additional, Diverio, Daniela, additional, Mancini, Marco, additional, Alimena, Giuliana, additional, Foà, Robin, additional, and Latagliata, Roberto, additional

Published
2019
Full Text
View/download PDF

5. Five Years after Frontline Tyrosine-Kinase Inhibitor (TKI) Treatment Initiation for Chronic Myeloid Leukemia: What Does It Happen in a Real-Life Setting?

Author

De Benedittis, Daniela, primary, Breccia, Massimo, additional, Carmosino, Ida, additional, Mariggiò, Elena, additional, Molica, Matteo, additional, Mohamed, Sara, additional, Massaro, Fulvio, additional, De Luca, Maria Lucia, additional, Scalzulli, Emilia, additional, Lisi, Chiara, additional, Passucci, Mauro, additional, Colafigli, Gioia, additional, Loglisci, Maria Giovanna, additional, Diverio, Daniela, additional, Mancini, Marco, additional, Foà, Robin, additional, and Latagliata, Roberto, additional

Published
2018
Full Text
View/download PDF

6. Clinical results according to age in patients with chronic myeloid leukemia receiving imatinib frontline: The younger, the later, the worse?

Author

Latagliata, Roberto, primary, Breccia, Massimo, additional, Carmosino, Ida, additional, Cesini, Laura, additional, De Benedittis, Daniela, additional, Mohamed, Sara, additional, Vozella, Federico, additional, Molica, Matteo, additional, Campanelli, Melissa, additional, De Luca, Maria Lucia, additional, Colafigli, Gioia, additional, Quattrocchi, Luisa, additional, Loglisci, Maria Giovanna, additional, Massaro, Fulvio, additional, Canichella, Martina, additional, Diverio, Daniela, additional, Mancini, Marco, additional, Alimena, Giuliana, additional, and Foà, Robin, additional

Published
2018
Full Text
View/download PDF

7. Impact of exclusion criteria for the DASISION and ENESTnd trials in the front-line treatment of a ‘real-life’ patient population with chronic myeloid leukaemia

Author

Latagliata, Roberto, primary, Carmosino, Ida, additional, Vozella, Federico, additional, Volpicelli, Paola, additional, De Angelis, Federico, additional, Loglisci, Maria Giovanna, additional, Salaroli, Adriano, additional, De Luca, Maria Lucia, additional, Montagna, Chiara, additional, Serrao, Alessandra, additional, Molica, Matteo, additional, Diverio, Daniela, additional, Nanni, Mauro, additional, Mancini, Marco, additional, Breccia, Massimo, additional, and Alimena, Giuliana, additional

Published
2015
Full Text
View/download PDF

8. Impact of exclusion criteria for the DASISION and ENESTnd trials in the front-line treatment of a 'real-life' patient population with chronic myeloid leukaemia.

Author

Latagliata, Roberto, Carmosino, Ida, Vozella, Federico, Volpicelli, Paola, De Angelis, Federico, Loglisci, Maria Giovanna, Salaroli, Adriano, De Luca, Maria Lucia, Montagna, Chiara, Serrao, Alessandra, Molica, Matteo, Diverio, Daniela, Nanni, Mauro, Mancini, Marco, Breccia, Massimo, and Alimena, Giuliana

Subjects
CHRONIC myeloid leukemia
Abstract

Both Dasision and ENESTnd trials had many exclusion criteria, with a possible selection bias compared with the real-life. To address the impact of this bias on the first-line treatment in the current clinical practice, we revised 207 unselected newly diagnosed chronic phase chronic myeloid leukaemia (CML) patients [M/F 108/99, median age 58.8 years, interquartile range 42.3-70.2] treated with front-line imatinib from June 2002 to June 2013 at our Institution, and evaluated how many of them would have been excluded from enrolment in the two trials. Twenty-eight patients (13.5%) should have been excluded by both trials because of polycomorbidities (12), severe cardiomyopathy (five), age > 80 with frailty (three), drug abuse (two) or other severe concomitant diseases (six). In addition, eight patients should have been excluded by Dasision due to isolated chronic obstructive broncopulmonar disease, and 19 patients should have been excluded by ENESTnd due to isolated diabetes (10), arrhythmia (four), acute myocardial infarction > 6 months before CML diagnosis (two), chronic pancreatic disease (two) and peripheral arterial obstructive disease (one). On the whole, 36 patients (17.4%) would have been excluded by Dasision trial and 47 (22.7%) by ENESTnd trial. The patients potentially not eligible for both trials were significantly older and with imatinib had a worse outcome compared with patients potentially eligible. Our data highlight that an automatic transposition of results available in clinical controlled trials into the frontline real-life management of CML patients should be regarded with caution. Copyright © 2015 John Wiley & Sons, Ltd. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

10. FLT3-ITD confers poor prognosis in patients with acute promyelocytic leukemia treated with AIDA protocols: long-term follow-up analysis.

Author

Breccia M, Loglisci G, Loglisci MG, Ricci R, Diverio D, Latagliata R, Foà R, and Lo-Coco F

Subjects
Adult, Follow-Up Studies, Humans, Idarubicin therapeutic use, Leukemia, Promyelocytic, Acute drug therapy, Prognosis, Prospective Studies, Time Factors, Treatment Outcome, Tretinoin therapeutic use, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Leukemia, Promyelocytic, Acute diagnosis, Leukemia, Promyelocytic, Acute genetics, Tandem Repeat Sequences genetics, fms-Like Tyrosine Kinase 3 genetics
Published
2013
Full Text
View/download PDF

11. Isodicentric duplication of Philadelphia chromosome as a mechanism of resistance to dasatinib in a patient with chronic myeloid leukemia after resistance to imatinib.

Author

Loglisci G, Breccia M, Nanni M, Mancini M, De Cuia R, Cannella L, Salaroli A, Federico V, Serrao A, Loglisci MG, Santopietro M, and Alimena G

Subjects
Aged, Benzamides, Chromosome Banding, Dasatinib, Female, Humans, Imatinib Mesylate, Piperazines administration & dosage, Protein Kinase Inhibitors therapeutic use, Pyrimidines administration & dosage, Thiazoles administration & dosage, Antineoplastic Agents therapeutic use, Chromosome Duplication genetics, Drug Resistance, Neoplasm genetics, Leukemia, Myelogenous, Chronic, BCR-ABL Positive drug therapy, Leukemia, Myelogenous, Chronic, BCR-ABL Positive genetics, Philadelphia Chromosome, Piperazines therapeutic use, Pyrimidines therapeutic use, Thiazoles therapeutic use
Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results